E FOR L AIM PUBLIC COMPANY LIMITEDSET: EFORL🇹🇭 TH

MD&A · 2024

Overview of Operations

Overview of Operations

Thailand's medical device industry is expected to grow steadily at approximately 8 percent, driven by the country's emergence as a Medical Hub in Asia, an aging population, and the rise of health tourism. These factors are encouraging hospitals to invest more in advanced medical devices and technologies. The demand for medical equipment, such as diagnostic machines, ventilators, and patient care devices, is increasing alongside the adoption of new technologies like Electronic Medical Records (EMR), AI, and cloud systems to enhance healthcare efficiency. The government also supports the nationwide implementation of EMR by 2025 to improve public health infrastructure and medical data connectivity. While these factors positively impact medical device manufacturers and distributors, they also intensify industry competition, requiring businesses to be well-prepared to meet market demands and maintain their competitive edge.

The growth of the medical device industry has resulted in the Company and its subsidiaries recorded total revenue of THB 1,354.60 million for the year ended 2024, representing an increase of THB 36.93 million or 3 percent compared to the previous year. Consequently, the Group reported a profit of THB 19.69 million in YE 2024, marking a 47 percent increase from the same period last year.


Operating Results & Financial Condition

Operating Results & Profitability


• Revenue from sales and services for the year 2024 amounted to THB 1,340.00 million (2023: THB 1,309.84 million), comprising revenue from the sale of medical equipment totaling THB 1,311.29 million (2023: THB 1,286.75 million) and service revenue of THB 28.71 million (2023: THB 23.10 million).

- Sales revenue mainly came from the sale of patient monitors/vitals signs monitor under the Nihon Kohden brand, anesthesia machines under the GE Healthcare brand, ventilators under the Hamilton brand, and other medical equipment. Most customers of the Company are government hospitals 67% and private hospitals 33%.

- Service revenue is primarily derived from maintenance services, which include maintenance contracts for customers both during and after the warranty period. Additionally, revenue comes from the rental of medical instruments and equipment, as well as other related services.

• Cost of sales and services consists of:

- Cost of good for sales: this include cost of medical devices and equipment, procurement costs, transportation fees, and import duties

- Cost of service: it comprises expenses for consumables, repair costs, employee-related expenses, product testing costs, and other related expenses.

• Gross margin for the year ended 2024 was THB 448.23 million, an increase of 2 percent compared to the same period last year. The gross profit margin ratio in YE2024 was 33.4 percent, a decrease of 0.1 percent compared to the same period last year.

• Other income includes interest income, gains from foreign exchange, gains from asset sales, and others.

In 2024, the Company’s other income of THB 14.59 million increased by 86% compared to 2023 (THB 7.83 million), mainly driven by gains from foreign exchange and gains from asset sales.

• Selling expenses mainly consist of salaries and benefits for sales staff, including travel expenses and sales and promotional expenses. Selling expenses for the year 2024 amounted to THB 267.32 million, an increase of 2% compared to the same period of the previous year (2023: THB 261.66 million), in line with the increase in sales.

• Administrative expenses include employee salaries, administrative expenses, depreciation, and various fees. Administrative expenses for the year 2024 amounted to THB 136.19 million, an increase of 2% compared to the same period of the previous year (2023: THB 134.12 million).

• Financial costs for the year ended 2024 amounted to THB 33.13 million, an increase of 7 percent compared to the same period last year (2023: THB 31.10 million), due to increased borrowing from other parties during the year.

• Net income/Loss The consolidated financial statements for YE2024 incurred net profit of THB 19.69 million, representing an increase of 47 percent compared to the same period (2023: 13.43 million) last year due to increased sales.





Other Analysis

TitleDescription
Financial position

Total Assets

As at 31 December 2024, the Company and its subsidiaries had total assets of THB 1,406.10 million, increasing by THB 37.77 million or 3 percent from 31 December 2023, mainly due to an increase in accounts receivable resulting from higher sales. Key financial data is presented as follows:

• The trade accounts receivable of the group as of 31 December 2024, amounted to THB 418.50 million, an increase of THB 97.87 million or 31% compared to the previous year, due to increased sales in 2024. The company's main customers are in the government sector; therefore, the likelihood of bad debt is minimal. Bad debts are more likely to occur among private sector customers. However, government sector customers typically have long collection periods due to procedural requirements and payment regulations. As a result, it is normal for trade accounts receivable in the medical equipment business to remain outstanding for more than 12 months, which is characteristic of medical device distributors.

• Inventory as at 31 December 2024, amounted to THB 367.05 million, a decrease of THB 46.02 million, or 11%, due to the Company's ongoing inventory management efforts.

• Restricted cash deposits as of 31 December 2024, amounted to THB 121.98 million and were related to a share sale and purchase agreement, in which the Company was sued as a defendant. The Court of First Instance and the Court of Appeal ruled against the Company, resulting in the Department of Legal Execution seizing the Company’s cash deposits. However, on 24 February 2025, the Supreme Court issued a final ruling in favor of the Company. The Company is currently in the process of filing a request with the Department of Legal Execution for the return of the funds.

• Property, plant and equipment as at 31 December 2024 amounted to THB 324.58 million, an increase of THB 9.33 million or 3% from the previous period due to a reduction in medical equipment. The land and buildings of the Company are pledged as collateral for a credit facility from a financial institution.


Total liabilities

Total liabilities as at 31 December 2024 was THB 861.78 million, increased by 18.08 million or 2 percent from the end of 2023, mainly due to higher trade payables for goods purchases.

• Short-term loans from other parties: The group obtained loans from other parties due to limited credit facilities for purchasing products. As at 31 December 2024, short-term loans from other parties amounted to THB 57.00 million with interest rates ranging from 12% to 14%. Some of these short-term loans are secured by third-party guarantees, with a guarantee fee of 2.00% per annum.

• Trade accounts payable - general suppliers as of 31 December 2024 amounted to THB 292.83 million, an increase of THB 114.40 million, or 64%, from the end of 2023, due to higher product purchases to support the Company's growing sales in 2024.

• Other payables - related parties as of 31 December 2024 amounted to THB 40.94 million, decreased by 13% from last year. This account relates to payables for medical device rental and other services.

• Short-term loans and accrued interest expenses - related parties as at 31 December 2024 amounted to THB 45.15 million, consisting of a principal amount of THB 42.00 million and accrued interest of THB 3.15 million. These loans were granted by directors in the form of promissory notes, bearing an interest rate of 5.00% - 6.00% per annum, and are repayable on demand without collateral.

• Loans from a related person (a relative of a director) as at 31 December 2024 amounted to THB 56.82 million, presented in the financial statements as follows:

- THB 11.96 million under current liabilities "Current portion of long-term loans from related person" and

- THB 44.86 million as "Long-term loans from related person".

Loan from a related person was initially incurred in 2021 for THB 83.75 million, with no collateral, and bears interest at MLR - 0.25% per annum. The Company is scheduled to repay the principal and interest in 84 installments of THB 1.00 million each. The remaining principal amount and interest will be fully repaid by 25 September 2028. The Company entered into a debt modification agreement to defer the repayment of the principal twice, making only interest payments during these periods, as follows:

- On 26 April 2023, the Company entered into a debt modification agreement to defer the repayment of the principal over 8 installments from May to December 2023.

- On 2 February 2024, the Company entered into a second debt modification agreement to defer the repayment of the principal over 8 installments from January to August 2024. The remaining outstanding balance will be fully repaid by 2028.

• Long term loans from shareholder and other party as at 31 December 2024 amounted to THB 182.48 million, presented in the financial statements as follows:

- THB 42.90 million under current liabilities " Current portion of long-term loans from shareholder and other parties" and

- THB 139.58 million under" Long-term loans from shareholder and other parties"

During 2021, the Company entered into loan agreements with four individuals and a related party, totaling Baht 335 million, to restructure debts at an interest rate of MLR-0.25% per annum. The principal and interest will be repaid over 84 installments of Baht 3.98 million each, with the remaining balance settled in the final installment by 25 September 2028.

The objective of these loans is to restructure the Company's debt, enabling repayment to a financial institution before the maturity date and reducing the interest burden. Additionally, the interest rate received is lower than that from banks, reducing the Company's commitment to its main bank and enabling it to seek funding from other sources in the future, thereby enhancing the Company's opportunities. The Company has changed the repayment conditions for long-term loans from a shareholder and other parties as follows:

- 26 April 2023 Defer the repayment of the principal amount from May 2023 to December 2023.

- 2 February 2024 Defer the repayment of the principal amount from January 2024 to August 2024.

- 30 September 2024 Repay only interest from September 2024 to January 2025 and repay principal amount (as newly agreed) with interest from February 2025 to December 2028.


Shareholders' Equity

• As at 31 December 2024, the Company and its subsidiaries had shareholders' equity of THB 544.31 million, an increase of THB 19.69 million, or 4 percent, from THB 524.62 million at the end of 2023. This was mainly due to strong operating performance in 2024.

Debt Securities with Financial Ratio Requirements

Debt Securities with Financial Ratio Requirements Issued?

No

Factors That May Affect Financial Condition

Factors or Incidents That May Materially Affect Financial Condition


1. External Factors

1.1 Economic and Social Trends

• Thailand's transition into an aging society is driving a continuous increase in demand for medical services and equipment.

• Growing consumer awareness of health is contributing to the expansion of the medical equipment market.

• The rise of medical tourism is prompting hospitals and healthcare centers to invest in advanced medical technology to accommodate both domestic and international patients.

1.2 Government Policies and Regulations

• The Ministry of Public Health's initiative to promote the adoption of Electronic Medical Records (EMR) presents an opportunity for the Company to expand its market in medical software and equipment.

1.3 Technology and Innovation

• The increasing use of artificial intelligence (AI) and automation in the healthcare industry enhances opportunities for developing software solutions, such as patient data analytics and decision-support systems for medical professionals.


2. Internal Factors

2.1 Market Expansion Strategy and Innovation

• The Company prioritizes the development of medical software, both proprietary solutions and imported technologies, to enhance its product offerings.

2.2 Impact of Legal Proceedings

• A legal dispute related to the sale of a subsidiary’s shares in 2017 previously posed financial risks to the Company. However, a Supreme Court ruling on February 24, 2025, dismissed the plaintiff’s claims, relieving the Company of any repayment obligations. This outcome reduces financial risk and strengthens investor confidence.

Considering the aforementioned factors, the Company has significant growth opportunities driven by the rising demand for medical equipment and supportive government policies. Furthermore, advancements in software technology and artificial intelligence will strengthen the Company's competitive position. Nevertheless, to ensure business stability and achieve sustainable returns for shareholders, the Company must carefully manage risks related to economic conditions, political developments, and long-term trends in the healthcare market.

Contents